Coverage
Filings
| Filing | Date |
|---|---|
| Transaction in Own Shares | 17 Nov 2025 |
| Transaction in Own Shares | 14 Nov 2025 |
| Director/PDMR Shareholding | 13 Nov 2025 |
| Transaction in Own Shares | 13 Nov 2025 |
| Block listing Interim Review | 12 Nov 2025 |
| Transaction in Own Shares | 12 Nov 2025 |
| Transaction in Own Shares | 11 Nov 2025 |
| GSK publishes provisional dividend dates | 10 Nov 2025 |
| Transaction in Own Shares |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 10 Nov 2025 |
| Transaction in Own Shares | 7 Nov 2025 |
| Transaction in Own Shares | 6 Nov 2025 |
| Transaction in Own Shares | 5 Nov 2025 |